

Supplementary Figures

Effects of the oral angiotensin-converting enzyme inhibitor captopril on occlusal-disharmony-induced cardiac dysfunction in mice

Aiko Ito ¹, Yoshiki Ohnuki ², Kenji Suita ², Ichiro Matsuo ^{1, 3}, Misao Ishikawa, ⁴, Yasumasa Mototani ², Kenichi Kiyomoto ^{2, 3}, Michinori Tsunoda ^{2, 3}, Akinaka Morii ^{2,3}, Megumi Nariyama ⁵, Yoshio Hayakawa ⁶, Hiroshi Tomonari ¹, Satoshi Okumura ²

¹ Department of Orthodontics, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan

² Department of Physiology, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan


³ Department of Periodontology, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan

⁴ Department of Oral Anatomy, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan

⁵ Department of Pediatric Dentistry, Tsurumi University School of Dental Medicine, Yokohama 236-8501, Japan


⁶ Department of Dental anesthesiology, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan

Supplementary Figure 1



Supplementary Figure 1. The original photo of **Fig. 1A**. The box outlined in black, indicated by the arrow, corresponds to the cropped parts shown in the main article.
arrow corresponds to the cropped part that is shown in the main article.


Supplementary Figure 2




Supplementary Figure 2. Daily consumptions of food and water. (A, B) No significant difference in daily consumption of food (A) or water (B) was observed at day 21 (black bars), compared to that at day 7 (white bars), by two-way ANOVA followed by the Bonferroni *post hoc* test.

Supplementary Figure 3

A




B




Supplementary Figure 3. Representative images of negative (**A**) and positive (**B**) controls for 8-OHdG immunostaining. Arrowheads indicates positive immunostaining. Scale bars: 20 μm

Supplementary Figure 4




Supplementary Figure 4. Representative full-length western blot. The amounts of activated AT1-AR (upper panel) and GAPDH (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 2C** in the main article.

Supplementary Figure 5




Supplementary Figure 5. Representative full-length western blot. The amounts of activated α -SMA (upper panel) and GAPDH (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 3C** in the main article.

Supplementary Figure 6




Supplementary Figure 6. Representative full-length western blot. The amounts of activated BAX (upper panel) and GAPDH (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot **in Fig. 4C** in the main article.

Supplementary Figure 7




Supplementary Figure 7. Representative full-length western blot. The amounts of activated NOX4 (upper panel) and GAPDH (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 5C** in the main article.

Supplementary Figure 8




Supplementary Figure 8. Representative full-length western blot. The amounts of activated XO (upper panel) and GAPDH (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 5D** in the main article.

Supplementary Figure 9




Supplementary Figure 9. Representative full-length western blot. The amounts of activated P-PKC (Tyr311) (upper panel) and T-PKC (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6A** in the main article.

Supplementary Figure 10




Supplementary Figure 10. Representative full-length western blot. The amounts of activated P-PKC (Thr-505) (upper panel) and T-PKC (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6B** in the main article.

Supplementary Figure 11




Supplementary Figure 11. Representative full-length western blot. The amounts of activated P-P38 (upper panel) and T-P38 (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6C** in the main article.

Supplementary Figure 12




Supplementary Figure 12. Representative full-length western blot. The amounts of activated P-ASK (Thy-845) (upper panel) and T-ASK (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6D** the main article.

Supplementary Figure 13




Supplementary Figure 13. Representative full-length western blot. The amounts of activated P-CaMKII (upper panel) and T-CaMKII (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6E** in the main article.

Supplementary Figure 14




Supplementary Figure 14. Representative full-length western blot. The amounts of activated ox-CaMKII (upper panel) and T-CaMKII (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 6F** in the main article.

Supplementary Figure 15




Supplementary Figure 15. Representative full-length western blot. The amounts of activated P-PLB (Thr-17) (upper panel) and T-PLB (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 7A** in the main article.

Supplementary Figure 16




Supplementary Figure 16. Representative full-length western blot. The amounts of activated P-PLB (Ser-16) (upper panel) and T-PLB (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 7B** in the main article.

Supplementary Figure 17



Supplementary Figure 17. Representative full-length western blot (lower panel) are shown. The box outlined in black in each panel, indicated an arrow, corresponds to the cropped part of the blot shown in **Fig. 7C** in the main article.

Supplementary Figure 18



Supplementary Figure 18. Representative full-length western blotting of Fig. 7D. The amounts of activated P-RYR (Ser-2808) (upper panel) and T-RYR (lower panel) are shown. The box outlined in black in each panel, indicated by an arrow, corresponds to the cropped part of the blot shown in **Fig. 7D** in the main article.